Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials

Pranita D. Tamma, Nirupama Putcha, Yong D. Suh, Kyle J. Van Arendonk, Michael L. Rinke

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: The emergence of multi-drug resistant Gram-negatives (MDRGNs) coupled with an alarming scarcity of new antibiotics has forced the optimization of the therapeutic potential of available antibiotics. To exploit the time above the minimum inhibitory concentration mechanism of β-lactams, prolonging their infusion may improve outcomes. The primary objective of this meta-analysis was to determine if prolonged β-lactam infusion resulted in decreased mortality and improved clinical cure compared to intermittent β-lactam infusion.Methods: Relevant studies were identified from searches of MEDLINE, EMBASE, and CENTRAL. Heterogeneity was assessed qualitatively, in addition to I2 and Chi-square statistics. Pooled relative risks (RR) and 95% confidence intervals (CI) were calculated using Mantel-Haenszel random-effects models.Results: Fourteen randomized controlled trials (RCTs) were included. Prolonged infusion β-lactams were not associated with decreased mortality (n= 982; RR 0.92; 95% CI:0.61-1.37) or clinical cure (n = 1380; RR 1.00 95% CI:0.94-1.06) compared to intermittent infusions. Subgroup analysis for β-lactam subclasses and equivalent total daily β-lactam doses yielded similar results. Most studies had notable methodological flaws.Conclusions: No clinical advantage was observed for prolonged infusion β-lactams. The limited number of studies with MDRGNs precluded evaluation of prolonged infusion of β-lactams for this subgroup. A large, multicenter RCT with critically ill patients infected with MDRGNs is needed.

Original languageEnglish (US)
Article number181
JournalBMC Infectious Diseases
Volume11
DOIs
StatePublished - Jun 22 2011
Externally publishedYes

Fingerprint

Lactams
Meta-Analysis
Randomized Controlled Trials
Confidence Intervals
Pharmaceutical Preparations
Anti-Bacterial Agents
Mortality
Microbial Sensitivity Tests
Critical Illness
MEDLINE

Keywords

  • β-lactams
  • Antibiotics
  • Infusion
  • Multi-drug resistant Gram-negatives

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. / Tamma, Pranita D.; Putcha, Nirupama; Suh, Yong D.; Van Arendonk, Kyle J.; Rinke, Michael L.

In: BMC Infectious Diseases, Vol. 11, 181, 22.06.2011.

Research output: Contribution to journalArticle

@article{ce6a16f74e3e4c2ea2041fe7c206c4a1,
title = "Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials",
abstract = "Background: The emergence of multi-drug resistant Gram-negatives (MDRGNs) coupled with an alarming scarcity of new antibiotics has forced the optimization of the therapeutic potential of available antibiotics. To exploit the time above the minimum inhibitory concentration mechanism of β-lactams, prolonging their infusion may improve outcomes. The primary objective of this meta-analysis was to determine if prolonged β-lactam infusion resulted in decreased mortality and improved clinical cure compared to intermittent β-lactam infusion.Methods: Relevant studies were identified from searches of MEDLINE, EMBASE, and CENTRAL. Heterogeneity was assessed qualitatively, in addition to I2 and Chi-square statistics. Pooled relative risks (RR) and 95{\%} confidence intervals (CI) were calculated using Mantel-Haenszel random-effects models.Results: Fourteen randomized controlled trials (RCTs) were included. Prolonged infusion β-lactams were not associated with decreased mortality (n= 982; RR 0.92; 95{\%} CI:0.61-1.37) or clinical cure (n = 1380; RR 1.00 95{\%} CI:0.94-1.06) compared to intermittent infusions. Subgroup analysis for β-lactam subclasses and equivalent total daily β-lactam doses yielded similar results. Most studies had notable methodological flaws.Conclusions: No clinical advantage was observed for prolonged infusion β-lactams. The limited number of studies with MDRGNs precluded evaluation of prolonged infusion of β-lactams for this subgroup. A large, multicenter RCT with critically ill patients infected with MDRGNs is needed.",
keywords = "β-lactams, Antibiotics, Infusion, Multi-drug resistant Gram-negatives",
author = "Tamma, {Pranita D.} and Nirupama Putcha and Suh, {Yong D.} and {Van Arendonk}, {Kyle J.} and Rinke, {Michael L.}",
year = "2011",
month = "6",
day = "22",
doi = "10.1186/1471-2334-11-181",
language = "English (US)",
volume = "11",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials

AU - Tamma, Pranita D.

AU - Putcha, Nirupama

AU - Suh, Yong D.

AU - Van Arendonk, Kyle J.

AU - Rinke, Michael L.

PY - 2011/6/22

Y1 - 2011/6/22

N2 - Background: The emergence of multi-drug resistant Gram-negatives (MDRGNs) coupled with an alarming scarcity of new antibiotics has forced the optimization of the therapeutic potential of available antibiotics. To exploit the time above the minimum inhibitory concentration mechanism of β-lactams, prolonging their infusion may improve outcomes. The primary objective of this meta-analysis was to determine if prolonged β-lactam infusion resulted in decreased mortality and improved clinical cure compared to intermittent β-lactam infusion.Methods: Relevant studies were identified from searches of MEDLINE, EMBASE, and CENTRAL. Heterogeneity was assessed qualitatively, in addition to I2 and Chi-square statistics. Pooled relative risks (RR) and 95% confidence intervals (CI) were calculated using Mantel-Haenszel random-effects models.Results: Fourteen randomized controlled trials (RCTs) were included. Prolonged infusion β-lactams were not associated with decreased mortality (n= 982; RR 0.92; 95% CI:0.61-1.37) or clinical cure (n = 1380; RR 1.00 95% CI:0.94-1.06) compared to intermittent infusions. Subgroup analysis for β-lactam subclasses and equivalent total daily β-lactam doses yielded similar results. Most studies had notable methodological flaws.Conclusions: No clinical advantage was observed for prolonged infusion β-lactams. The limited number of studies with MDRGNs precluded evaluation of prolonged infusion of β-lactams for this subgroup. A large, multicenter RCT with critically ill patients infected with MDRGNs is needed.

AB - Background: The emergence of multi-drug resistant Gram-negatives (MDRGNs) coupled with an alarming scarcity of new antibiotics has forced the optimization of the therapeutic potential of available antibiotics. To exploit the time above the minimum inhibitory concentration mechanism of β-lactams, prolonging their infusion may improve outcomes. The primary objective of this meta-analysis was to determine if prolonged β-lactam infusion resulted in decreased mortality and improved clinical cure compared to intermittent β-lactam infusion.Methods: Relevant studies were identified from searches of MEDLINE, EMBASE, and CENTRAL. Heterogeneity was assessed qualitatively, in addition to I2 and Chi-square statistics. Pooled relative risks (RR) and 95% confidence intervals (CI) were calculated using Mantel-Haenszel random-effects models.Results: Fourteen randomized controlled trials (RCTs) were included. Prolonged infusion β-lactams were not associated with decreased mortality (n= 982; RR 0.92; 95% CI:0.61-1.37) or clinical cure (n = 1380; RR 1.00 95% CI:0.94-1.06) compared to intermittent infusions. Subgroup analysis for β-lactam subclasses and equivalent total daily β-lactam doses yielded similar results. Most studies had notable methodological flaws.Conclusions: No clinical advantage was observed for prolonged infusion β-lactams. The limited number of studies with MDRGNs precluded evaluation of prolonged infusion of β-lactams for this subgroup. A large, multicenter RCT with critically ill patients infected with MDRGNs is needed.

KW - β-lactams

KW - Antibiotics

KW - Infusion

KW - Multi-drug resistant Gram-negatives

UR - http://www.scopus.com/inward/record.url?scp=79959337263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959337263&partnerID=8YFLogxK

U2 - 10.1186/1471-2334-11-181

DO - 10.1186/1471-2334-11-181

M3 - Article

C2 - 21696619

AN - SCOPUS:79959337263

VL - 11

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

M1 - 181

ER -